A brief overview of myeloproliferative neoplasms and the associated signs and symptoms commonly presenting in patients.

A review of systemic treatment options used in polycythemia vera and the roles these play in the current treatment landscape.

Panel experts share insight regarding prognosis for patients with polycythemia vera and the associated risk for progression to myelofibrosis.

Shared insight on classification, risk factors, and important biomarkers and pathways in myelofibrosis.

Comprehensive discussion highlighting diagnostic and molecular testing involved in the diagnosis of myelofibrosis, challenges related to early diagnosis, and consideration factors for assessing prognostic risk.

Expert perspectives on how to identify and assess patients with myelofibrosis for transplant therapy.

Panel experts briefly review supporting data for the use of JAK inhibitors in myelofibrosis and discuss the impact of emerging data on the current treatment landscape.

Shared insights on monitoring strategies for myelofibrosis, including important considerations for patients receiving treatment with JAK inhibitors.

Expert perspectives on treatment sequencing strategies with JAK inhibitors for myelofibrosis.

Focused discussion on emerging trial data surrounding novel, investigational therapies for myelofibrosis.

A review of recent trial data evaluating combination therapy approaches with ruxolitinib in myelofibrosis, including the rationale and potential clinical benefits associated with the use of these emerging strategies.

Shared closing thoughts on the future treatment landscape for myeloproliferative neoplasms, including future and emerging areas of research and remaining areas of unmet need.